EN DE

CU Medical Systems Inc (115480) Fair Value & Analysis

Healthcare · KR · Market cap 21.5B KRW

CM CU Medical Systems Inc 115480 · KQ
Price2,280 KRW
Fair Value1,134 KRW
Upside-50.3%
Quality76/100
Watch CU Medical Systems Inc for free, get notified when fair value or trend changes. Watch for free

Strengths

Healthy Growth
Low debt · generates free cash flow
Ranks above peers (6/9)

Risks

!Trades 50% ABOVE our fair value of 1,134 KRW
!Loss over the last twelve months · -6.5% net margin · fiscal year 2025 1.7%
!Moderate moat 46/100
Healthy Growth
Loss over the last twelve months · -6.5% net margin · fiscal year 2025 1.7%
Low debt · generates free cash flow
Ranks above peers (6/9)
Moderate moat 46/100
Evidence: High Range 850.60 KRW – 1,418 KRW Share as image

Fair value as of: Aug 19, 2026

From 24 valuation models · updated yesterday

Share price +28.4% over the past month.

A strong business, but screening 50% overvalued on our models.

What matters now

  • A high-quality business (quality 76/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
  • The price sits above even our optimistic bull case (1,418 KRW). The favourable scenario is already priced in.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

9,035 KRW 1,705 KRW Fair Value 1,134 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.

How to read this chart

60‑month range 1,705 KRW – 9,035 KRW · fair‑value band 850.60 KRW – 1,418 KRW · the 2,280 KRW price screens above the 1,134 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

CU Medical Systems Inc (115480) currently trades at 2,280 KRW, while our model-based Fair Value estimate is 1,134 KRW, implying the stock looks roughly 50.3% overvalued today. The Quality Score stands at 76/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, CU Medical Systems Inc generated revenue of 45.0B KRW at a net margin of -6.5%. Revenue grew 56.9% year over year. Net debt stands at 13.7B KRW. Fundamentals as of Aug 19, 2026

Our scenario range runs from 850.60 KRW (bear case) to 1,418 KRW (bull case); at 2,280 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 28% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -10% fair-value upside, at -50%, 115480 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 5,920 KRW 9,059 KRW 13,558 KRW 80
Rev-Margin DCF 5,601 KRW 9,302 KRW 13,555 KRW 74
ROIC Compounder 5,761 KRW 7,491 KRW 9,600 KRW 72
All 24 models by family
DCF Models
FCF DCF 5,810 KRW 9,356 KRW 14,768 KRW 38
Owner Earnings 1,827 KRW 3,155 KRW 5,181 KRW 31
5Y Revenue Exit 5,601 KRW 9,297 KRW 14,002 KRW 39
5Y EBITDA Exit 7,166 KRW 12,225 KRW 18,122 KRW 41
5Y P/E Exit 2,154 KRW 2,848 KRW 3,517 KRW 38
10Y Revenue Exit 5,424 KRW 8,817 KRW 13,353 KRW 36
10Y EBITDA Exit 6,615 KRW 10,850 KRW 16,499 KRW 37
10Y P/E Exit 3,419 KRW 4,339 KRW 5,350 KRW 35
Earnings-Based
Graham-Dodd 350.55 KRW 1,091 KRW 1,451 KRW 54
Lynch FV 237.09 KRW 338.69 KRW 440.30 KRW 50
PEG = 1.0 237.09 KRW 338.69 KRW 440.30 KRW 46
EPV 5,416 KRW 6,411 KRW 7,282 KRW 59
Multiples
P/E Multiple 850.60 KRW 1,134 KRW 1,418 KRW 63
P/S Multiple 657.28 KRW 876.37 KRW 1,095 KRW 58
P/B Multiple 657.28 KRW 876.37 KRW 1,095 KRW 55
EV/EBIT 8,328 KRW 11,289 KRW 14,250 KRW 53
EV/EBITDA 8,936 KRW 12,100 KRW 15,264 KRW 54
EV/Revenue 5,784 KRW 8,502 KRW 11,219 KRW 43
Asset-Based
NCAV (Graham) 1,878 KRW 2,516 KRW 3,755 KRW 50
Growth DCF
Growth DCF 5,920 KRW 9,059 KRW 13,558 KRW 80
Rev-Margin DCF 5,601 KRW 9,302 KRW 13,555 KRW 74
Economic Profit
Residual Income 2,592 KRW 2,424 KRW 1,821 KRW 61
ROIC Compounder 5,761 KRW 7,491 KRW 9,600 KRW 72
Growth Earnings
Growth-Adj P/E 699.87 KRW 999.82 KRW 1,300 KRW 68

Widest divergence: Growth DCF (9,059 KRW) versus Earnings-Based (338.69 KRW). Highest evidence: Growth DCF (80).

Notify me when 115480 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 45.0B KRW
Revenue growth (YoY) +56.9%
Net margin -6.5%
Return on equity -693%
Free cash flow 8.9B KRW FY2025
Operating margin 23.9%
More key figures
EPS growth (YoY) +1,617%
Net debt 13.7B KRW FY2025

Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 76/100

Of which business quality 72 · Market factors (momentum, volatility) 28

Profitability 28
Margins and returns on capital today
Quality Growth 91
Are margins and returns improving?
Cashflow 86
Earnings quality: real cash, not paper profit
Fin. Strength 59
Balance sheet, leverage, solvency risk
Investment 92
Disciplined investing over empire-building
Low Volatility 57
Calm price path (market factor)
Momentum 13
Price trend over the last 3–12 months (market factor)
52W Momentum 20
Distance to the 52-week high (market factor)
Net Issuance 100
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

CU Medical Systems, Inc. manufactures and sells defibrillators worldwide. The company offers automatic external defibrillators (AEDs), mechanical cardiopulmonary resuscitation systems, healthcare and rehabilitation products, AED trainers, and sterilizers/disinfectors. It also resells Apple products, including Mac, iPad, and iPod.

Full company description

CU Medical Systems, Inc. manufactures and sells defibrillators worldwide. The company offers automatic external defibrillators (AEDs), mechanical cardiopulmonary resuscitation systems, healthcare and rehabilitation products, AED trainers, and sterilizers/disinfectors. It also resells Apple products, including Mac, iPad, and iPod. The company was founded in 2001 and is headquartered in Wonju-si, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

CU Medical Systems Inc reported revenue of 48.2B KRW in FY2025 versus 35.4B KRW in FY2021, a compound +8.0%/yr. Reported net income was 819M KRW in FY2025.

Growth Quality 84/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
48.2B KRW
Latest YoY
+18.7%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+0.9%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+11.2%
Avg. growth/yr (13Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.4%
Revenue +8.0%/yr
FY21 35.4B KRW
FY22 47.0B KRW
FY23 41.8B KRW
FY24 40.6B KRW
FY25 48.2B KRW
Net income
FY21 −14.0B KRW
FY22 9.4B KRW
FY23 −8.2B KRW
FY24 −3.2B KRW
FY25 819M KRW

115480 screens 50% overvalued. Compare with InBody Co →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "CU Medical Systems Inc Fair Value". https://www.fairvalue-calculator.com/stock/115480

Peer Group

Health Care · 2314 stocks

How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)

Quality Score 76 · Top 25%
Fair Value upside −50% · Below median
Return on assets 8% · Top 25%
Net margin (TTM) -6% · Bottom 25%
Operating margin (TTM) 24% · Top 25%
Revenue growth 57% · Top 25%
Debt / equity 0.46× · Higher than 75% of peers

Valuation Multiples vs Health Care median · lower = cheaper

P/FCF 0.0× · Cheaper than 75% of peers
EV/EBITDA 0.7× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE100 · sector 21
PAST0 · sector 13
HEALTH77 · sector 96
DIVIDEND0 · sector 32

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).

Stock Price Fair Value vs Fair Value
InBody Co 041830 67,400 KRW 49,984 KRW -26%
i-SENS, Inc 099190 18,480 KRW 8,168 KRW -56%
Value Added Technology Co 043150 20,950 KRW 60,242 KRW +188%
Mediana Co 041920 10,070 KRW 6,289 KRW -38%
Meta Biomed Co 059210 3,980 KRW 9,268 KRW +133%
Sewoon Medical Co 100700 2,300 KRW 6,054 KRW +163%
MEKICS CO., Ltd 058110 1,642 KRW 1,581 KRW -4%
PeopleBio, Inc 304840 561.00 KRW 504.98 KRW -10%
Novartis AG NVSN 2,742 MXN 1,952 MXN -29%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,944 ₹989.50 -49%

Compare CU Medical Systems Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Evidence & backtest 34 years, survivorship-adjusted Financial calculators DCF, Graham, PEG and more

Frequently asked questions

Is CU Medical Systems Inc (115480) overvalued or undervalued?
As of Aug 19, 2026, our model estimates a fair value of 1,134 KRW versus a price of 2,280 KRW, about −50% (overvalued).
What is the fair value of 115480?
Our model-based fair value for CU Medical Systems Inc is 1,134 KRW (as of Aug 19, 2026), built from audited fundamentals. The current price: 2,280 KRW.
What is the quality score of 115480?
CU Medical Systems Inc has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of CU Medical Systems Inc (115480)?
CU Medical Systems Inc reported trailing-twelve-month revenue of about 45.0B KRW (latest available figure, as of Aug 19, 2026).
What is the net profit margin of 115480?
The net profit margin of CU Medical Systems Inc is about -6.5%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track CU Medical Systems Inc and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.